Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a biotech firm specializing in extended-release drug delivery technology, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The company is making waves with its proprietary DiffuSphere™ technology and has reported positive trial results for its osteoarthritis knee pain treatment. Eupraxia is also progressing with treatments for conditions like eosinophilic esophagitis and is actively developing a pipeline of other long-acting formulations.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
